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Abstract
 
Granulocyte/macrophage colony-stimulating factor (GM-CSF)–induced monocyte-derived
macrophages (GM-M
 
 
 
) are permissive to M-tropic HIV-1 entry, but inhibit viral replication
at posttranscriptional and translational levels, whereas M-CSF-induced macrophages (M-M
 
 
 
)
produce a large amount of HIV-1. M-M
 
 
 
 express a high level of Hck and a large isoform of
C/EBP
 
 
 
, and HIV-1 infection increases the expression of Hck but not of C/EBP
 
 
 
. GM-M
 
 
 
express a high level of C/EBP
 
 
 
 and a low level of Hck, and HIV-1 infection drastically in-
creases the expression of a short isoform of C/EBP
 
 
 
 but decreases that of Hck.
Treatment of M-M
 
 
 
 with antisense oligonucleotide for Hck (AS-Hck) not only suppresses
the expression of Hck, but also stimulates the induction of the short isoform of C/EBP
 
 
 
 and
inhibits the viral replication. Treatment of GM-M
 
 
 
 with a moderate amount of AS-C/EBP
 
 
 
not only inhibits the expression of the small isoform of C/EBP
 
 
 
 preferentially, but also stim-
ulates the induction of Hck and stimulates the virus production at a high rate. These results
suggest that CSF-induced and HIV-1–mediated distinct regulation of Hck and small isoform of
C/EBP
 
 
 
 represent the heterogeneous susceptibility of tissue M
 
 
 
 to HIV-1 infection, and the
regulation of Hck and C/EBP
 
 
 
 are closely related and these two molecules affect one another.
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Introduction
 
Monocytes/macrophages (Mo/M
 
 
 
)
 
*
 
 are a major target of
HIV type I (HIV-1) infection and serve as a reservoir for
viral persistence in vivo (1, 2). Most tissue M
 
 
 
 are permis-
sive to macrophage (M)-tropic virus entry and release a
small amount of virus particles in the asymptomatic carrier
(3, 4), but they occasionally produce a large amount of viral
particles in the AIDS patients or HIV-1 patients compli-
cated with opportunistic infection (5, 6). Recent studies
suggest that anti–HIV-1 therapy (highly active antiretrovi-
ral therapy) strongly inhibits HIV-1 replication at levels of
RT activity and viral DNA replication in aggressively di-
vided T cells, and reduces viral antigenemia (7, 8). HIV-1–
infected Mo/M
 
 
 
 in some lymphoreticular tissue, however,
cannot be removed by this therapy, and the residual cells
can generate and spread virus particles in the human body
(9, 10). In contrast to the advanced and profound studies of
the T-tropic HIV-1 replication system on both the viral
and host sides, the precise mechanism of M-tropic HIV-1
replication in Mo/M
 
 
 
 are not fully understood, but is a
key factor in the control of HIV-1 suffering.
A nonreceptor type of Src-like tyrosine kinase, human
hematopoietic cell kinase (Hck), primarily expressed in
neutrophils and M
 
 
 
, induces other cellular kinase activa-
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*
 
Abbreviations used in this paper:
 
 A-M
 
 
 
, alveolar macrophages; AS, anti-
sense; AZT, azidothymidine; C/EBP
 
 
 
, CCAAT enhancer binding pro-
tein; GM-M
 
 
 
, GM-CSF–induced human monocyte-derived macro-
phages; Hck, hematopoietic cell kinase; L/S ratio of C/EBP
 
 
 
, the relative
amounts of the large isoform (37 kD) to the small isoform (23 kD) of
 
C/EBP
 
 
 
; M-CSF, macrophage-CSF; M
 
 
 
, macrophages; M-M
 
 
 
,
M-CSF–induced human monocyte-derived macrophages; Mo, mono-
cytes; M-tropic, macrophage-tropic; NS, nonsense; S, sense.T
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Hck and C/EBP
 
 
 
 Decide HIV-1 Susceptibility of M
 
 
 
tion (11, 12), and can bind to HIV-1 Nef at its SH3 do-
main to change it active form (13, 14). Nef is known to
promote high HIV-1 and simian immunodeficiency virus
(SIV) replication in vitro and progress AIDS-like disease in
monkey (15, 16, 17). In addition, transfection of Hck to
human 293 T cells partially helps HIV-1 entry and transac-
tivation of HIV-1 LTR promoter region (18).
In contrast to Hck, CCAAT-enhancer binding protein
(C/EBP
 
 
 
) is widely expressed, and has large and small iso-
form generated by alternative initiation of protein transla-
tion from a single transcript (19, 20). A mutant HIV-1 that
lacks C/EBP
 
 
 
 binding sites of the HIV-1LTR promoter
region cannot replicate in macrophage-lineage U937 cells
(21), and cotransfection of the HIV-1-LTR construct and
C/EBP
 
 
 
 expression plasmids strongly activates the HIV-1
promoter in NTera-2 cells (22). In contrast, induction of a
small isoform of C/EBP
 
 
 
 by mycobacterium infection and
IFN-
 
 
 
 strongly inhibits HIV-1 replication in macrophage-
lineage THP-1 cells and alveolar M
 
 
 
 (A-M
 
 
 
; references
23 and 24). These findings suggest that both types of
C/EBP
 
 
 
 isoforms have exactly opposite effects for HIV-1
replication; large isoform stimulates but small isoform in-
hibits the HIV-1 replication.
In the present study, we show that human Mo-derived
M
 
 
 
 induced by macrophage CSF (M-CSF) and by GM-
CSF (M-M
 
 
 
 and GM-M
 
 
 
, respectively) are distinct in
their susceptibility to M-tropic HIV-1 infection via differ-
ent basal- and HIV-1–mediated expression of Hck and
small isoform of C/EBP
 
 
 
.
 
Materials and Methods
 
Preparation and Culture of M
 
 
 
.
 
Mo were obtained from
PBMCs of normal healthy volunteers using a magnetic cell sepa-
ration system (MACS; Miltenyi Biotec) with anti-CD14 mAb
coated microbeads as described previously (25).
CD14
 
 
 
 Mo were cultured in RPMI 1640 medium (Nissui
Seiyaku Co., Ltd.), 3 mg/ml of a filtered glutamine (Sigma-
Aldrich), 100 U/ml penicillin G potassium (Banyu Seiyaku Co.,
Ltd.), 100 
 
 
 
g/ml streptomycin (Meiji Seika Co., Ltd.), 10% of
autoclaved NaHCO
 
3
 
, 10% heat-inactivated FCS (Z.L. Bockneck
Laboratories Inc.) with the following human recombinant cyto-
kines at optimal concentrations: 5 ng/ml GM-CSF (Schering-
Plough Japan) or 50 ng/ml M-CSF (Morinaga Milk Industry
Co., Ltd.) at 37
 
 
 
C in humidified 5% CO
 
2
 
 for 7 d. During the cul-
ture, Mo differentiated to M
 
 
 
 (26).
 
Preparation and Activation of CD4
 
 
 
T cells.
 
CD4
 
 
 
T cells were
positively isolated from CD14
 
 
 
 PBMCs by using a MACS with
anti-CD4 mAb coated microbeads. The selected cell population
was 
 
 
 
93% positive for CD3 and CD4. CD4
 
  
 
T cells were stimu-
lated for 5 d with PHA (10 
 
 
 
g/ml) and IL-2 (30 U/ml) (Genzyme).
 
HIV-1 Strains and Infection.
 
HIV-1
 
BaL
 
 and HIV-1
 
JR-FL
 
 was
collected from culture supernatant of these viral HIV-1 strains-
infected M-M
 
 
 
 as a viral resource. M
 
 
 
s were incubated for 2 h
at 37
 
 
 
C with 100 pg/ml p24 antigen of DNase-treated viral su-
pernatant (p24, the 50% tissue culture infective dose (TCID
 
50
 
)
and multiplicity of infection (MOI) are 50 ng/ml, 
 
 
 
3,000 and
0.05, respectively) and then cultured in RPMI 1640 containing
10% FCS and CSF. If necessary, the viral innocula was pretreated
with 100 
 
 
 
M azidothymidine (AZT) for 2 h at 4
 
 
 
C. Fresh cul-
ture medium containing CSF was added every 3–4 d (20% of the
volume; references 23 and 27). Heat-inactivated virus (1 h,
56
 
 
 
C) was used as negative control. The kinetics of viral produc-
tion were followed by sequential measurement of p24 antigen in
supernatants by an ELISA using a combination of two antibodies:
anti-
 
gag
 
-p24 monoclonal antibody (Nu24) and peroxidase-
labeled 10B5 (28). For detection of the intracellular p24 distribu-
tion, cells were fixed with 100% ethanol and stained with Nu24
using a commercial kit (Histofine: SAB-PO(M) kit; Nichirei
Co., Ltd. Tokyo).
 
Detection of HIV-1 DNA by Nested PCR and Semi-Dilution
PCR.
 
Cell lysates were prepared in 100 
 
 
 
l of lysis buffer con-
taining 10 mM Tris-HCl (pH 8.3), 0.5% Tween 20, 0.5% Noni-
det P-40, 0.5 mM EDTA, and 100 mg of proteinase K per ml,
and then incubated at 55
 
 
 
C for 1 h. Crude DNA was isolated by
nucleic acid extraction kit (IsoQuick; Microprobe Co., Ltd.) and
75% ethanol precipitation, and then dissolved in TE (pH 8.3).
DNA samples (200 ng) were added to 0.5 
 
 
 
M each primer and
0.2 
 
 
 
M each dNTP, 1.5 mM MgCl
 
2
 
, and 1 U 
 
Taq
 
 DNA poly-
merase (Takara Biomedicals) in 50 
 
 
 
l final volume. After 3 min at
95
 
 
 
C, 30 cycles were performed in an automated DNA Thermal
Cycler (PerkinElmer), consisting of 30 s at 95
 
 
 
C, annealing at
55
 
 
 
C, and extension at 72
 
 
 
C for 1 min. HIV LTR and 
 
gag
 
primers were JAM 62 (5
 
 
 
-GCTTCAAGTAGTGTGTGC-
CCGTCTG-3
 
 
 
) and JAM65 (5
 
 
 
-AATCGTTCTAGCTCCCT-
GCTTGCCC-3
 
 
 
). For the nested PCR, 10 
 
 
 
l of amplified prod-
ucts were submitted to another 30-cycle amplifications under
the same conditions using internal primers JAM 63 (5
 
 
 
-GTG-
TGACTCTGGTAACTAGAGATCC-3
 
 
 
) and JAM 64 (5
 
 
 
-
CCGCTTAATACTGACGCTCTCGCAC-3
 
 
 
) (28). The am-
plification products were analyzed by electrophoresis on 2%
agarose gel stained with ethidium bromide for UV visualization
(expected size of HIV is DNA 245 bp).
Serially diluted DNA samples (diluted with DNA from unin-
fected M
 
 
 
) were added to the PCR mixture containing 5
 
 
 
-LTR
primers, LTR5 (5
 
 
 
-GGCTAACTAGGGAACCCACTG-
CTT-3
 
 
 
) and LTR6 (5
 
 
 
-CTGCTAGAGATTTTCCACACT-
GAC-3
 
 
 
), and amplified as described above. PCR products were
subjected with 2% agarose gel and capillary transferred to a nylon
membrane (Pall BioSupport) with mild alkali digestion. The
membrane was prehybridized, and hybridized with [
 
 
 
-
 
32
 
P] ATP
labeled JAM 62 in 20
 
 
 
 SSC, 100
 
 
 
 Denhart solution, 20% SDS,
5% sodium pyrophosphate, and 5 mg/ml yeast RNA for 1.5 h
and overnight, respectively. The blots were washed 4 times with
2
 
 
 
 SSC and 1% SDS, and then analyzed using a Fuji BAS 2000
bioimage analyzer (Fuji Photo Film Co., Ltd.; expected size of
HIV DNA 190 bp). The threshold limitation of the PCR prod-
uct was determined with serial dilutions of 8E5/LAV cells (1
copy/cell), and was 1 copy/10
 
4 
 
cells.
 
Detection of C/EBP  mRNA by RT-PCR. Total RNA was
isolated using RNA-Bee™ isolation of RNA (TEL-TEST, Inc.),
and reverse-transcribed by MMLV (USB) and random primer
(Takara Biomedicals). Semiquantitative RT-PCR reactions were
then performed for 35 cycles using normalized cDNAs and re-
combinant Taq DNA polymerase. The cycling parameters were
denaturation at 95 C for 30 s, annealing at 60 C for 30 s, and ex-
tension at 72 C for 1 min. PCR products were separated on aga-
rose gel and visualized by ethidium bromide staining. The primer
sequences used were: C/EBP  sense primer 5 -ACAGCGAC-
GAGTACAAGATCC-3 ; antisense primer 5 -GCAGCTGCT-
TGAACAAGTTCC-3  (29), G3PDH sense primer 5 -CCT-
TCATTGACCTCAACTAC-3 ; antisense primer 5 -AGTG-
ATGGCATGGACTGTGGT-3  (25).T
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In Vitro Kinase Assay and Immunoblot Analysis. Hck protein
from M  lysates was immunoprecipitated with anti-p56/59hck
antibody (N-30; Santa Cruz Biotechnology, Inc.) and recovered
by absorption to protein A/G-PLUS Sepharose (30, 31). Kinase
activity for Hck was performed with 20  l kinase buffer contain-
ing 1  g of the tyrosine kinase substrate p50 (GST fusion protein
containing residues 331–443 of the Src substrate protein Sam 68
(51 kD); Santa Cruz Biotechnology, Inc.) and 5 Ci of [ -32P]
ATP (3,000 Ci/mmol; NEN Life Science Products) for 15 min at
30 C, and then measured with liquid scintillation counting. The
radiolabeled p50 were subjected with SDS-PAGE and visualized
by autoradiography.
Immunoblot analysis were performed in M  lysates with rab-
bit polyclonal antibody against Hck (N-30) or C/EBP  (C-19;
Santa Cruz Biotechnology, Inc.) (32).
Antisense Treatment of Hck and C/EBP . Phosphorothioate-
modified antisense oligonucleotides for Hck (AS-Hck; 5 -
TTCATCGACCCCATCCTGGC-3 ) and C/EBP  (AS-C/
EBP ; 5 -CAGGCGTTGCATGAACGCGG-3 ), and their cor-
responding sense oligonucleotides (S-Hck; 5 -GCCAGGATG-
GGGTCGATGAA-3  and S-C/EBP ; 5 -CCGCGTTCATG-
CAACGCCTG-3 ), and their unrelated nonsense oligonucleotides
(NS-Hck; 5 -CCATATTTCCCGCTCGCGTG-3  and NS-
C/EBP ; 5 -CCAGAGAGGGCCCGTGTGGA-3 ) were syn-
thesized (33, 34). A total of 2–10  M of each oligonucleotide
was incubated with serum-free RPMI 1640 medium for 15 min
after the medium was preincubated with 5  l lipofectin (Life
Technologies) per ml for 30 min. Cells were incubated for 24 h
in each oligonucleotide containing medium with 10% FCS and
CSF, washed, and then cultured with HIV-1 strains as described
above.
Statistical Analysis. Statistical analysis of the data was per-
formed using Student’s t test. P values  0.01 were considered
significant. The experiments shown are representatives of three to
seven independent experiments.
Results
Different Susceptibility of Mo-derived M-M  and GM-M 
to M-tropic HIV-1. We first examined M-M  and GM-
M  for their capacity to replicate M-tropic HIV-1 strains,
HIV-1JR-FL and HIV-1BaL. M-M  produced a large
amounts of HIV-1JR-FL or HIV-1BaL, whereas GM-M 
produced no or a more limited levels of HIV-1. P24 levels
of HIV-1BaL are 28–59 ng/ml versus 0–0.5 ng/ml (n   3),
and those of HIV-1JR-FL are 7.8–8.6 ng/ml versus 0–0.27
ng/ml (n   3) on 10 d postinfection (PI), in M-M  versus
GM-M , respectively (Fig. 1 A). 
Syncitia and multinucleated giant cells appeared from d
4–7 PI in HIV-1JR-FL– or HIV-1BaL–exposed M-M  but
not in GM-M . Immunohistological study showed that
p24 antigen is strongly expressed in HIV-1–infected
M-M , and the viral spreading is observed not only in
syncitia and multinucleated giant cells but also in their sur-
rounding cells (unpublished data). 
To investigate whether GM-M  are permissive to
HIV-1 entry, we examined the existence of the viral DNA
at 2 d PI by nested PCR using a pair primer designed from
HIV-1 LTR-gag region. Both M s produced the viral
DNA of HIV-1JR-FL and HIV-1BaL (Fig. 1 B). As viral in-
nocula are often contaminated with viral DNA, we dem-
onstrated that viral DNA products of HIV-1BaL were not
detected in both M-M  and GM-M  when the viral in-
nocula was preincubated with RT inhibitor AZT (Fig. 1 C).
Next, levels of HIV-1BaL infectivity in these M s were as-
sessed by a single step PCR using a pair primer designed
from the HIV-1LTR region. Frequencies of viral DNA in
105 cells of M-M  and GM-M  at 2 d PI were almost
same and were  10–102 copies. At 4 d PI, the frequency
of viral DNA in GM-M  remained 10–102 copies,
whereas those in M-M  increased to 103-104 copies (Fig.
1 D) which were similar levels to those observed in a pre-
vious study (28).
Figure 1. Different susceptibility of Mo-derived M s to M-tropic
HIV-1 infection. (A) Measurement of viral production at the indicated
days in the culture supernatants by p24-ELISA. The data shown are rep-
resentative one of three independent experiments. (B) Detection of viral
DNA in total DNA from M  lysates at 2 d PI by nested PCR using a
specific outer- and inner-primer for HIV-1 LTR-gag region. (C) Detec-
tion of viral DNA by a single step PCR in M  infected by AZT-pre-
treated (AZT) or not treated ( ) viral innocula of HIV-1BaL. The data
shown here are representative one of three independent experiments. (D)
Estimation of HIV-1BaL DNA levels by semi-dilution PCR using a spe-
cific primer for the HIV-1 LTR region. The levels of viral DNA in in-
fected M  were compared with that of NL4–3 in 8E5 cells.T
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Different Expression of Hck in M-M  and GM-M  Before
and After HIV-1 Infection. M  express Hck that can bind
to HIV-1 Nef (13, 14). Then we examined the expression
of Hck in M-M  and GM-M  by immunoblots. Before
HIV-1 infection, the levels of 56 and 59 kD of Hck protein
in M-M  were  5 times of that in GM-M  (PSL of Hck
in M-M  and GM-M  are 105.1   1.54 and 16.7  
1.13, respectively; Fig. 2 A). Compared with these M s,
PBMC and PHA-activated CD4 T cells did not express
Hck and the level of Hck in Mo was significantly low (Fig.
2 A).
On d 2 PI of HIV-1BaL, the expression of Hck signifi-
cantly increased in M-M  but markedly reduced in GM-
M , and the difference of M-M  and GM-M  was  25
times (PSL of Hck in HIV-1 infected-M-M  and -GM-
M  are 17.6   1.0 and 0.66  0.14, respectively; Fig. 2
B). A similar result was observed in HIV-1JR-FL-exposed
M-M  and GM-M  (unpublished data). To confirm the
HIV-1 induced up- or down-regulation of Hck expression
in M-M  and GM-M , an in vitro kinase assay of Hck
from these M s was performed using GAP-associated pro-
tein Sam 68 (51 kD) as a tyrosine kinase substrate (Fig.
2 C). In agreement with the results of immunoblot analysis,
Hck activity on d 2 PI of HIV-1BaL augmented in M-M 
but reduced in GM-M , and the difference of M-M  and
GM-M  was  25 times.
Different Expression of C/EBP  in M-M  and GM-M 
Before and After HIV-1 Infection. Previous studies indicate
that large isoform and short isoform of C/EBP  stimulates
and inhibits the HIV-1 replication in M , respectively (21,
23). To investigate the possibility that the difference in the
expression of the C/EBP  isoforms correlates with the dis-
tinct susceptibility to HIV-1 replication in M-M  and
GM-M , we examined the expression of C/EBP  iso-
forms in M-M  and GM-M  before and after HIV-1 in-
fection by immunoblots. Before HIV-1 infection, the lev-
els of C/EBP  protein in GM-M  were much higher
than that in M-M . The small isoform (23 kD) was espe-
cially detectable in GM-M  but not in M-M , and the
relative amounts of the large band (37 kD) to the small
band (23 kD; L/S ratio) of C/EBP  in M-M  and GM-
M  were 13.3   0.78 and 1.32   0.13, respectively (Fig.
3 A). In contrast to these M s, both PBMCs and Mo
showed very low level expression of C/EBP , and the ex-
pression of C/EBP  in PHA-activated CD4 T cells re-
sembled that of M-M .
On 2 d PI of HIV-1BaL, the bands of C/EBP  in-
creased significantly in GM-M , especially a strong in-
duction of the small isoform of C/EBP  was observed,
and the L/S ratio of C/EBP  markedly reduced from
1.48   0.07 to 0.23   0.08. In contrast to GM-M , the
amount of C/EBP  and the L/S ratio of C/EBP  were
not changed significantly in M-M  by HIV-1BaL infec-
tion (L/S ratio of C/EBP  in M-M  with and without
infection were 12.3   0.76 and 13.2   0.56, respec-
tively; Fig. 3 B). Similar results were also observed in
HIV-1JR-FL-exposed M-M  and GM-M  (unpublished
data).
Antisense Oligonucleotide for Hck Inhibits the HIV-1 Replica-
tion in M-M . The data described above suggest the pos-
sibility that highly active Hck can trigger HIV-1 replication
in M-M . We then examined whether down-regulation
of Hck by antisense treatment reduces the ability of M-M 
to support viral replication. Treatment with the antisense
oligonucleotide probe of Hck (2  M; AS-Hck) but not
with the unrelated (NS-Hck) or sense (S-Hck) probe
Figure 2. Immunoblot analysis and in vitro kinase assay of Hck in
M-M  and GM-M . (A) Immunoblots of Hck protein in PBMC,
PHA-activated CD4 T cells, Mo, and Mo-derived M s. (B) Immuno-
blots of Hck protein in HIV-1BaL–infected M-M  and GM-M  at 2 d
PI. The relative amounts of the Hck in cells were measured using NIH
image software (PSL; photo stimulating luminescence, A/mm2). (C) In
vitro kinase assay of Hck in HIV-1BaL–infected Mo-derived M s. Hck
protein was immunoprecipitated by a specific antibody against p56/59Hck,
and reacted with a kinase buffer containing the tyrosine kinase substrate p50
(Sam 68) in the presence of [ -32P] ATP. The samples were resolved in
SDS-PAGE and autoradiography or blotted with anti-Hck antibody. The
data shown here are representative one of three independent experiments.T
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markedly reduced the amount of Hck protein in M-M ,
and the level became less than one-tenth at 48 h (the level
of Hck in M-M  treated with AS-Hck was 0.10   0.004
times of that in M-M  treated with Lipofectin alone; Fig.
4 A). After infection with HIV-1BaL, the expression of Hck
still reduced in AS-Hck-treated M-M  (the level of Hck
in HIV-1 infected M-M  treated with AS-Hck was 0.11 
0.003 times of that in HIV-1 infected M-M  treated with
lipofectin alone; Fig. 4 A), and the AS-Hck treated M-M 
showed a markedly reduced viral production compared
with NS-Hck– or S-Hck–treated M-M  (Fig. 4 B). How-
ever, the viral DNA was detectable in AS-Hck-treated
M-M  (Fig. 4 C).
To confirm that anti–HIV-1 effect of AS-Hck is due to
the specific inhibition of Hck activity, and is not the non-
specific effect of the probe, we examined the effect of the
AS-Hck on the replication of T-tropic HIV-1 replication
in PHA-activated CD4  T cells that do not express Hck.
The AS-Hck did not inhibit T-tropic HIV-1NL4–3 replica-
tion in the CD4 T cells (Fig. 4 D). These findings suggest
Figure 3. Immunoblot analysis of C/EBP  in M-M  and GM-M .
(A) Immunoblots of C/EBP  protein in PBMC, PHA-activated CD4  T
cells, Mo, and Mo-derived M s. (B) Immunoblots of C/EBP  protein in
HIV-1BaL–infected M-M  and GM-M  at 2 d PI. The relative amounts
of the large band to the small band (L/S ratio) of C/EBP  were calculated
using PSL values of 37 kD and 23 kD of C/EBP  isoforms. The data
shown here are representative one of three independent experiments.
Figure 4. Translational suppression of Hck expression by the antisense
oligonucleotide probe inhibits HIV-1BaL replication in M-M . (A) Im-
munoblot analysis of Hck in M-M  treated with oligonucleotide probes
for Hck (2  M) (AS, AS-Hck; NS, NS-Hck; S, S-Hck; and L, lipofectin
alone) at 24 h (left) and in HIV-1BaL–infected M-M  pretreated with the
corresponding probes at 7 d PI, respectively (right). The data shown are
representative one of three independent experiments. (B) Kinetics of the
p24 levels in the culture supernatants of the oligonucleotide-pretreated
HIV-1BaL–infected M-M . (C) Detection of viral DNA in the oligonu-
cleotide-pretreated HIV-1BaL–infected M-M  by nested PCR. The data
shown are representative one of seven independent experiments. (D) p24
levels in AS-Hck or AS-C/EBP –treated PHA-activated CD4 T cells in-
fected by HIV-1NL4–3 (1 ng/ml) at 7 d PI. AS-Hck or AS-C/EBP  has no
effect on T-tropic HIV-1 replication in PHA-activated CD4 T cells.T
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that active Hck protein is absolutely required for M-tropic
HIV-1 replication in M .
Dominant Repression of the Small Isoform of C/EBP  by
Antisense Oligonucleotide for C/EBP  Triggers HIV-1 Replica-
tion in GM-M . As the immunoblot analysis of C/EBP 
in M-M  and GM-M  described above, and the previous
studies (23, 24) provide the possibility that dominant ex-
pression of a small isoform of C/EBP  is correlated with
repression of HIV-1 replication in GM-M , we investi-
gated whether changes in the expression of C/EBP  iso-
forms can account for the induction of HIV-1 replication
in GM-M . 
The treatment of GM-M  with the antisense oligonu-
cleotide probe of C/EBP  (2  M; AS-C/EBP ) but not
with the unrelated (NS-C/EBP ) or sense (S-C/EBP )
probe markedly decreased the expression of the small iso-
form of C/EBP  but not the large isoform of C/EBP ,
and significantly increased the L/S ratio of C/EBP  (L/S
ratio of GM-M  treated with AS-C/EBP , S-C/EBP ,
NS-C/EBP , and Lipofectin alone were 2.18   0.09, 1.50  
0.17, 1.46   0.08, and 1.45   0.08, respectively; Fig.
5 A). When these oligonucleotides probe-treated GM-M 
were infected with HIV-1BaL, the L/S ratio of C/EBP  in-
creased in AS-C/EBP –treated GM-M  but not in NS-
C/EBP – or S-C/EBP –treated GM-M  (L/S ratio of
HIV-1 infected GM-M  treated with AS-C/EBP , S-C/
EBP , NS-C/EBP , and Lipofectin alone were 3.13  
0.31, 0.39   0.07, 0.40   0.04, and 0.50   0.08, respec-
tively; Fig. 5 A). Consistent with the increase in the L/S ra-
tio of C/EBP , a large amount of viral particles were pro-
duced from AS-C/EBP –treated GM-M  but not from
NS-C/EBP – or S-C/EBP –treated GM-M  (Fig. 5 B).
The viral DNA was detectable in each oligonucleotide
probe-treated GM-M  (Fig. 5 C).
We next examined the dose response effect of AS-C/
EBP  on the expression of C/EBP  and the HIV-1 repli-
cation in GM-M . When GM-M  was treated with 1–2
 M of AS-C/EBP , the expression of large isoform of
C/EBP  did not change significantly, but that of small
isoform of C/EBP  decreased in a dose response manner,
and L/S ratio of C/EBP  increased in these M  with the
maximal increase at 2  M (L/S ratio at 2  M were 2.2;
Fig. 6 A). In consistent with the increase of L/S ratio of
C/EBP , HIV-1 replication occurred in a dose response
manner in GM-M  treated with 1–2  M of AS-C/
EBP  (Fig. 6 B). When GM-M  were treated with
higher concentration (5–10  M) of AS-C/EBP , how-
ever, the reduced expression of not only a small isoform
but also a large isoform of C/EBP  was observed (Fig.
6 B). The L/S ratio of C/EBP  in GM-M  treated with
5  M was almost the same as that in GM-M  treated with
1  M, and both M  trigger the same level of viral pro-
duction (Fig. 6 B). The L/S ratio of C/EBP  in GM-M 
treated with 10  M of AS-C/EBP  was the similar level
to that of nontreated GM-M  and no viral replication
was observed in the GM-M  (Fig. 6 B). Blocking effect
of antisense oligonucleotide is thought mainly due to the
inhibition of translation. Our results also showed that AS-
C/EBP  did not significantly affect the expression of the
mRNA (Fig. 6 C). 
As AS-C/EBP  did not affect HIV-1NL4–3 replication in
PHA-activated CD4 T cells, the effect of AS-C/EBP  on
HIV-1 replication by the modulation of the L/S ratio of
C/EBP  was specifically active in GM-M  (Fig. 4 D).
These findings suggest that the large isoform of C/EBP  is
necessary for M-tropic HIV-1 replication in M  and the
small isoform of C/EBP  has a deep association with the
repression of M-tropic HIV-1 in GM-M .
Treatment of M-M  with AS-Hck and of GM-M  with
AS-C/EBP  Modulates the Expression of C/EBP  in M-M 
and Hck in GM-M , Respectively. As already shown, a
high level of Hck and repression of the small isoform of
C/EBP  are observed in HIV-1 susceptible M-M . In
Figure 5. Translational inhibition of C/EBP  expression by the anti-
sense oligonucleotide probe triggers HIV-1BaL replication in GM-M .
(A) Immunoblot analysis of C/EBP  in GM-M  treated with oligonu-
cleotide probes for C/EBP  (2  M; AS, AS-C/EBP ; NS, NS-C/
EBP ; S, S-C/EBP ; and L, lipofectin alone) at 24 h (left), and HIV-1BaL–
infected GM-M  pretreated with the corresponding probes at 7 d PI,
respectively (right). The data shown are representative one of three in-
dependent experiments. (B) Kinetics of p24 levels in the culture super-
natants of the oligonucleotide-pretreated HIV-1BaL–infected GM-M .
(C) Detection of viral DNA in the oligonucleotide-pretreated HIV-1BaL–
infected GM-M  by nested PCR. The data shown are representative
one of three independent experiments.T
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contrast, a low level of Hck and dominant expression of the
small isoform of C/EBP  are observed in HIV-1 resistant
GM-M . We also showed that treatment of M-M  with
AS-Hck inhibits the viral replication, and treatment of
GM-M  with AS-C/EBP  stimulates the viral replica-
tion. These results indicate that the phenotype of AS-Hck–
treated M-M  and AS-C/EBP –treated GM-M  are
similar to that of GM-M  and M-M  in their susceptibil-
ity for HIV-1 replication, respectively. Then we examined
whether treatment of M-M  with AS-Hck and of GM-
M  with AS-C/EBP  changes the expression of C/EBP 
in M-M  and Hck in GM-M , respectively. Treatment
of M-M  with AS-Hck (2  M) suppressed the expression
of Hck but stimulated the expression of the short isoform
of C/EBP  and decreased the L/S ratio (Fig. 7). When
AS-Hck–treated M-M  were infected with HIV-1BaL,
similar results were obtained (Fig. 7). Treatment of GM-
M  with AS-C/EBP  (2  M) not only reduced the ex-
pression of a short isoform of C/EBP  but also stimulated
the expression of Hck (Fig. 7). Similar results were ob-
tained when AS-C/EBP –treated GM-M  was infected
with HIV-1BaL (Fig. 7). As well as the data shown in Figs.
4, 5, and 6, viral replication was inhibited in AS-Hck–
treated M-M  and a large amount of viral particles were
produced from AS-C/EBP –treated GM-M .
These results strongly suggest that Hck and C/EBP  are
closely related and these two molecules affect one another,
and the regulation of Hck and small isoform of C/EBP 
contribute to determine distinct susceptibility of M  to
HIV-1 infection.
Discussion
In the present study, we found an evidence that Mo-
derived M-M  and GM-M  are distinct in their suscepti-
bility to M-tropic HIV-1 infection; M-M  releases a large
amount of HIV-1 particles whereas GM-M  does not
produce or produce a very low level of the viral replica-
tion, but the viral DNA was detectable at similar levels in
both M s. These findings suggest that the inhibition of
HIV-1 replication in GM-M  occurs at posttranscriptional
and translational levels but not at the viral entry. In fact,
HIV-1 coreceptors, CD4 and CCR5, are equally expressed
in both M s (27, and our unpublished data), and CCR5
and CXCR4 are fully expressed in CSF-induced Mo-
derived M s and A-M  (35, 36, 37). 
Previously, we reported that viral DNA of M-tropic
HIV-1PAR was detected in both M-M  and GM-M , but
the viral replication was mainly observed in M-M  (27).
Thus, M-M  is ubiquitously susceptible to many strains of
M-tropic HIV-1, but GM-M  inhibits the viral replica-
tion at the transcriptional and translational levels. In rela-
tion to this point, it is reported that M  generated from
Mo by human serum produce a large amount of M-CSF by
HIV-1 infection, and the addition of a specific antibody
against M-CSF markedly reduces HIV-1 production in
these M  (38). 
In some studies, GM-CSF augments M-tropic HIV-1
replication in human Mo-derived M  (39, 40). Mo-
derived M  used in that study, however, is different from
that used in our present study, because they generated M 
from Mo by human serum and examined the effect of GM-
CSF on the M , but we examined the M  generated di-
rectly from Mo by GM-CSF or M-CSF. Thus, the differ-
ence in the effect of GM-CSF on HIV-1 replication may
depend on the difference in M  origin.
In the present study, we showed that the CSF-induced
basal- and HIV-1–induced difference in the expression of
Hck and C/EBP  isoforms deeply contributes to deter-
mine the tissue- or cell stage–specific differences of viral
replication in M . M-M  possess high levels of both the
Figure 6. Effects of different concentrations of AS-C/EBP  on the ex-
pression of protein and mRNA of C/EBP  and HIV-1BaL replication in
GM-M . (A) Effect of different concentrations of AS-C/EBP  on the
expression of C/EBP  protein. (B) Dependence of HIV-1BaL replication
in GM-M  on the alternative L/S ratio of C/EBP  expression. (C) Effect
of different concentrations of AS-C/EBP  on the expression of C/EBP 
mRNA. GM-M  were treated with various concentrations (1–10  M)
of AS-C/EBP  for 24 h, and then infected with HIV-1BaL. Cell lysates for
immunoblot and mRNA were obtained 2 d and 1 d after infection, respec-
tively. p24 levels of the culture supernatants obtained 7 d after infection
much correspond with the alternative L/S ratio of C/EBP  expression
(AS, AS-C/EBP ; NS, NS-C/EBP ; S, S-C/EBP ; and L, lipofectin
alone). The data shown are representative one of two experiments.T
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protein and kinase activity of Hck, and HIV-1 infection
triggers to augment them, whereas GM-M  express about
fivefold lower levels of both the protein and kinase activity
of Hck, and HIV-1 infection reduces the levels to an unde-
tectable one. Final difference of the expression of Hck be-
tween M-M  and GM-M  was  25-fold. Furthermore
we provide an evidence that translational inhibition of Hck
by AS-Hck can fully inhibit HIV-1 replication in M-M 
although viral DNA is detected in the treated M . Thus,
the present observations suggest that the high basal level
and HIV-1–mediated activation of Hck activity greatly
contributes to produce HIV-1 replication in M , and the
repression and reduction of Hck activity maintains nonpro-
ductive (latent) infection of HIV-1 in M . However, the
underlying mechanism that induces such a distinct modula-
tion of the expression of Hck is presently unclear.
In contrast to Hck, the roles of C/EBP  in M-tropic
HIV-1 replication in M  are very flexible and confused,
because the large (37 kD) and small (23 kD) isoforms of
C/EBP  generated by alternative initiation of protein trans-
lation from a single transcript (19, 20) are reciprocal effec-
tors; the former is required for the viral replication in Mo/
M  but not CD4 T cells (21), whereas the latter acts as a
dominant negative transcription factor (23, 24, 41). Our
present data coincide with those previous study, because
large isoform of C/EBP  are dominant in HIV-1 suscepti-
ble M-M , but basal- and HIV-1–mediated dominant ex-
pression of small isoform of C/EBP  are observed in HIV-1
resistant GM-M . Furthermore our data show that de-
crease of small isoform of C/EBP  and increase in the L/S
ratio of C/EBP  by treatment with a low dose of AS-C/
EBP  strongly stimulates the viral replication in HIV-1–
resistant GM-M . These findings indicate that the large
isoform of C/EBP  is a stimulator and the small isoform is
a inhibitor in the process of HIV-1 replication in Mo/M 
and also suggest that human tissue M  can convert their
phenotype for M-tropic HIV-1 replication from resistant
to susceptible one via the modulation of the L/S ratio of
C/EBP  expression in vivo. 
At present we do not know the precise mechanism of
the preferential suppression of the small isoform by a low
concentration of AS-C/EBP . One possible explanation is
that the dominant expression of the small isoform of
C/EBP  usually occurs in GM-M  as seen in Fig. 3 B,
then the small isoform is dominantly suppressed. Different
protein isoforms can be produced for C/EBP  by alterna-
tive use of translation initiation codons in the same mRNA
molecule (20, 42, 43, 44). So it is also possible to consider
that the AS-C/EBP  we used in this study (corresponding
to the ATG sequence of the human C/EBP  gene [34])
preferentially affects the translation initiation site for the
short isoform, and if we used another antisense oligonucle-
otide, then different results would be obtained.
Our present investigation using AS-Hck and AS-C/
EBP  presents the new and interesting finding that the
regulation of Hck and C/EBP  are closely related and
these two molecules affect one another. Hck is a ki-
nase, and may directly or indirectly affect the expres-
sion of the short isoform of C/EBP . The promoter
region of Hck, however, does not contain a C/EBP 
binding site (45, 46). At present we do not know the
precise mechanism of connection between Hck and
Figure 7. Immunoblot analy-
sis of C/EBP  in M-M  treated
with AS-Hck and of Hck in
GM-M  treated with AS-C/
EBP  with or without HIV-1BaL
infection M-M  and GM-M 
were treated with AS-Hck
(2   M), AS-C/EBP  (2  M)
and lipofectin alone (L) for 24 h.
These M s were infected with
or without HIV-1BaL, and cul-
tured for 48 h with M-CSF and
GM-CSF, respectively. Cell ly-
sates were obtained at indicated
time points after antisense oligo-
nucleotide treatment. The data
shown are representative one of
two experiments.T
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C/EBP , and studies to clarify the mechanism are un-
der way. 
Several studies showed that A-M  from healthy volun-
teers do not stimulate the HIV-1 replication in vitro, but
viral DNA formation occurs in the A-M , and A-M 
from an HIV-1 carrier contains very few copies of the
HIV-1 genome and hardly produces HIV-1 particles (3, 4).
Furthermore it is reported that a small isoform of C/EBP 
is dominant in A-M  (23, 24). Our previous report indi-
cate that phenotype of GM-M  closely resembles that of
human A-M  in their morphology, cell surface antigen
expression, and several functions including resistance to
H2O2-mediated cytotoxicity, H2O2 release, and catalase ac-
tivity (26, 32). In this study, we demonstrated that GM-
M  dominantly expresses small isoform of C/EBP , and
hardly stimulates HIV-1 replication, though viral DNA is
formed, indicating GM-M  also resembles A-M  in their
susceptibility to HIV-1 infection. Therefore, analysis of re-
sistance of GM-M  to HIV-1 replication can help to re-
solve the latent infection of nonactivated A-M .
A-M  from the progressor patients or patients with op-
portunistic infection, however, often produces a large
amount of viral particles and spreads HIV-1 infection in
lung tissue (5, 6, 24). In the present study, we showed that
the phenotype of GM-M  in HIV-1 infection can change
from resistant to susceptible one after the treatment with
AS-C/EBP . In some studies, A-M  from the active sites
of inflammation express high levels of CD14 and c-fms
gene (47, 48). Previously we reported that M-M  that can
support HIV-1 replication also express these markers (25,
32). In addition recent study showed that addition of acti-
vated allogeneic lymphocytes reduces the expression of
small isoform of C/EBP  in A-M  or THP-1 cells (49).
These findings suggest the possibility that a phenotypic
change of resident A-M  from resistant to susceptible one
for HIV-1 replication, and/or an influx of blood Mo-
derived M  with high adaptability to HIV-1 replication
occurs in the inflammatory lung and can account for their
permissivity to M-tropic HIV-1 replication in vivo.
In conclusion, the findings of the present study strongly
suggests that regulation of Hck activity and selective ex-
pression of C/EBP  isoforms greatly contribute to deter-
mine distinct susceptibility of Mo-derived M-M  and
GM-M  to M-tropic HIV-1 infection. M  heterogeneity
induced by CSF during M  differentiation from precursors
plays an important role for the distinct susceptibility against
HIV-1. The present model of a distinct adaptability of
GM-M  and M-M  to M-tropic HIV-1 through the reg-
ulation of their cellular proteins represents heterogeneous
susceptibility of tissue M  to HIV-1 infection in vivo, and
may help to develop a new anti–HIV-1 drug for preven-
tion of persistent infection in human tissue Mo/M .
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